缬沙坦对慢性肾功能衰竭患者血清氨基末端脑钠肽前体及血、尿转化生长因子β1 水平的影响

梁  飞

（珠海高新技术产业开发区金鼎社区卫生服务中心，广东  珠海，519085）

中图分类号：R692.6       文献标识码：A    文章编号：1674-7860（2016）15-0019-02   证型：BGD

【摘  要】目的：探析缬沙坦对慢性肾功能衰竭患者血清氨基末端脑钠肽前体及血、尿转化生长因子β₁水平的影响。方法：随机抽取我院及珠海市人民医院门诊与住院部在2015年1月—2016年2月诊治的180例血肌酐非透析性慢性肾功能衰竭患者，分为两组，一组患者未实施干预，另一组患者使用缬沙坦进行干预，对比与统计分析两组患者的NT-proBNP与TGF-β₁。结果：对照组患者的血尿TGF-β₁的差异性不显著（P＞0.05）。干预组患者治疗前12周的血尿TGF-β₁的差异性显著（P＜0.05）。但治疗后12周的血尿TGF-β₁的差异性不显著（P＞0.05）。干预组患者治疗前后的NT-proBNP分别是（739.6±85.6）pg/ml、（197.2±57.3）pg/ml，对照组分别是分别是（757.7±42.1）pg/ml、（291.0±78.1）pg/ml，干预组改善程度明显优于对照组，差异性显著（P＜0.05）。结论：缬沙坦降低慢性肾功能衰竭患者的NT-proBNP与TGF-β₁，控制患者病情的发展。

【关键词】缬沙坦；慢性肾功能衰竭；NT-proBNP；TGF-β₁

【Abstract】Objective: To explore the effect of valsartan on serumN-terminal pro brain natriuretic peptide and serum and urine levels oftransforming growth factor β₁ in patients with chronic renal failure.Method:180 non dialysis chronicrenal failure patients with serum creatinine, who were treated in theoutpatient and inpatient department of our hospital and Zhuhai People'sHospital from January 2015 to February 2016, were randomly divided into twogroups, one group (the control group) received no intervention while the othergroup (the intervention group) received the intervention of valsartan, NT-proBNPand TGF-β₁ of patients intwo groups were compared and statistically analyzed. Result:Thedifference of serum and urine levels of TGF-β₁ of patients in the controlgroup was not significant (P＞0.05). The difference of serum and urinelevels of TGF-β₁ ofpatients in the intervention group 12 weeks before the treatment wassignificant (P＜0.05) whilethe difference 12 weeks after the treatment was not significant (P＞0.05). TheNT-proBNP of patients in the intervention group before and after treatment was(739.6±85.6) pg/ml and (197.2±57.3)pg/ml respectively while that of the control group was (757.7±42.1)pg/ml and (291.0±78.1) pg/mlrespectively, the improvement of the intervention group was significantlybetter than that of the control group, the difference was statistically significant (P＜0.05).Conclusion:Valsartan couldeffectively decrease the NT-proBNP and TGF-β₁ of patients with chronic renal failure and control the development of the disease.

【Keywords】Valsartan; chronic renal failure; NT-proBNP；TGF-β₁

doi:10.3969/j.issn.1674-7860.2016.15.009

参考文献：

[1]赵爱国,郭小云,夏天,等.氨基末端脑钠肽前体在慢性肾功能衰竭合并心力衰竭的诊断价值[J/CD].中华临床医师杂志:电子版,2011,05(3):726-730.

[2]蔡世红.缬沙坦联合低分子肝素对早期糖尿病肾病尿白蛋白排泄率的影响[J].江苏医药,2003,29(12):938-939.

[3]胡菊兰,周群,傅龙梅,等.高剂量缬沙坦治疗慢性肾脏病尿蛋白疗效观察[J].中国实用医药,2011,06(19):173-174.

[4]曾春艳,周晓明.缬沙坦联合阿魏酸钠治疗慢性肾功能衰竭疗效观察[J].中国医药导报,2007,4(33):27-28.

[5]蓝天座,闵亚丽,于黔,等.缬沙坦联合氟伐他汀钠对维持性血液透析患者微炎症状态的影响[J].中国药业,2008,17(7):58-59.

[6]张冉,熊佩华,张玲,等.慢性肾功能衰竭患者尿转化生长因子β₁的检测及临床意义[J].苏州大学学报(医学版),2006,26(3):450-452.

基金项目：

珠海市医学科研基金项目（项目编号: 2015J008）。

作者简介：

梁飞（1977-），广东珠海人，女，主治医师，大学本科，主要研究方向：普通内科。

详情请浏览《中医临床研究》2016第15期